Sharma Vijay, Sharma Savitri, Garg Prashant, Rao Gullapalli N
Aberdeen Royal Infirmary, Scotland.
Indian J Ophthalmol. 2004 Dec;52(4):287-92.
To review the in vitro susceptibility and the clinical response to 0.3% ciprofloxacin in Staphylococcus aureus keratitis.
This is a non-comparative case series derived from a prospectively collected database and analysed retrospectively. One hundred and twenty one patients presenting in the cornea service of LV Prasad Eye Institute, Hyderabad, India, between January 1993 and December 2000, and identified to have S. aureus keratitis were included in the study. All patients had received slitlamp evaluation of the cornea and diagnostic microbiologic workup. They were treated with topical antimicrobial therapy based on smear and culture results. All S. aureus isolates were tested for antibiotic susceptibility by disk diffusion and those resistant to ciprofloxacin were confirmed by testing for minimum inhibitory concentration. The patients' clinical response to the antimicrobial therapy was noted.
Twenty-five (20.6%) of 121 isolates resistant to ciprofloxacin on in vitro susceptibility testing were further analysed in this study. Fifteen of these 25 (60%) patients were initially treated with topical ciprofloxacin. Twelve of 15 (80%) patients showed no clinical improvement (3-8 days). Based on antibiotic susceptibility results, the antibiotic therapy was modified to fortified cefazolin and gentamicin in seven (58.3%), to vancomycin in one and to chloramphenicol in four cases. The corneal infiltrate resolved in 11 (73.3%) of 15 cases. Two patients required penetrating keratoplasty (PK), one required evisceration, and one patient was lost to follow up. Nine of 25 patients were initially started on fortified cefazolin and gentamicin therapy based on smear positive for gram-positive cocci; this resulted in resolution of infiltrate in 44.4% (4/9) while three required change of antibiotics (vancomycin-2, chloramphenicol-1), one required PK and one patient was lost to follow up. One of 25 patients started and continued on chloramphenicol, showed no response and required PK.
This study shows a significant resistance of S. aureus to many antibiotics including ciprofloxacin and highlights the need for an alternative to ciprofloxacin monotherapy for the treatment of staphylococcal keratitis.
回顾金黄色葡萄球菌性角膜炎对0.3%环丙沙星的体外敏感性及临床反应。
这是一个非对照病例系列,来源于前瞻性收集的数据库并进行回顾性分析。纳入1993年1月至2000年12月期间在印度海得拉巴LV普拉萨德眼科研究所角膜科就诊、确诊为金黄色葡萄球菌性角膜炎的121例患者。所有患者均接受了角膜裂隙灯检查和诊断性微生物学检查。根据涂片和培养结果给予局部抗菌治疗。所有金黄色葡萄球菌分离株均采用纸片扩散法检测抗生素敏感性,对环丙沙星耐药的菌株通过检测最低抑菌浓度进行确认。记录患者对抗菌治疗的临床反应。
本研究进一步分析了121株在体外药敏试验中对环丙沙星耐药的菌株中的25株(20.6%)。这25例患者中有15例(60%)最初接受局部环丙沙星治疗。15例患者中有12例(80%)在3至8天内无临床改善。根据抗生素敏感性结果,7例(58.3%)患者的抗生素治疗改为强化头孢唑林和庆大霉素,1例改为万古霉素,4例改为氯霉素。15例患者中有11例(73.3%)角膜浸润消退。2例患者需要穿透性角膜移植术(PK),1例需要眼球摘除术,1例患者失访。25例患者中有9例最初基于革兰氏阳性球菌涂片阳性开始使用强化头孢唑林和庆大霉素治疗;这导致浸润消退的比例为44.4%(4/9),而3例需要更换抗生素(2例换为万古霉素,1例换为氯霉素),1例需要PK,1例患者失访。25例患者中有1例开始并持续使用氯霉素,无反应,需要PK。
本研究表明金黄色葡萄球菌对包括环丙沙星在内的多种抗生素存在显著耐药性,并强调治疗葡萄球菌性角膜炎需要环丙沙星单药治疗的替代方案。